Dividend Contenders List: Top 15

4. Pfizer Inc. (NYSE:PFE)

Dividend Yield as of November 11: 6.40%

Pfizer Inc. (NYSE:PFE) is an American multinational pharmaceutical and biotech company. Some investors might feel pessimistic about the company’s prospects, anticipating setbacks as COVID-related sales decrease and patents on key drugs expire. However, this outlook may be overly negative. Pfizer is actively working on a weight loss pill that it expects could be among the first of its kind to reach the market soon. In addition, the company’s strength lies in its diversified portfolio as it has always shown solid growth across multiple segments.

In the third quarter of 2024, Pfizer Inc. (NYSE:PFE) reported revenue of $17.7 billion, which saw a 32% growth from the same period last year. The revenue surpassed analysts’ estimates by $2.83 billion. During the quarter, the company also achieved remarkable growth in its Oncology segment. Notable revenue contributions came from products like Padcev, Xtandi, Lorbrena, and Braftovi/Mektovi, alongside meeting increased demand for Paxlovid during the recent COVID-19 surge.

Pfizer Inc. (NYSE:PFE) has increased its 2024 full-year revenue guidance by $1.5 billion at the midpoint, bringing the projected range to $61.0 to $64.0 billion. Additionally, it raised its adjusted diluted EPS guidance by $0.30 at the midpoint, now expecting $2.75 to $2.95 per share. This updated EPS guidance reflects the company’s strong year-to-date performance and sustained confidence in its business.

On October 9, Pfizer Inc. (NYSE:PFE) declared a quarterly dividend of $0.42 per share, which was in line with its previous dividend. The company has been making regular dividend payments to shareholders for the past 85 years and maintains a 14-year streak of consistent dividend growth. As of November 11, the stock has a dividend yield of 6.4%.